PM360

APRIL 7, 2023

However, Medicare will only be able to negotiate prices for 10 Part D drugs in 2026, another 15 Part D drugs in 2027, another 15 Part D and Part B drugs in 2028, and another 20 Part D and Part B drugs for 2029 and subsequent years. It’s amazing we still separate the drug costs from overall healthcare costs,” Sontupe says.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

European Pharmaceutical Review

JUNE 16, 2023

According to Maximize Market Research , new technologies are expected to boost the clinical trials market between 2022 to 2029, especially as the industry and patients are shifting towards digitalisation approaches and personalised medicines. As the data landscape evolves, what is the most exciting innovation in clinical data management.

Safety 111

Safety Electronics Recruitment Patients 111

European Pharmaceutical Review

AUGUST 30, 2022

Nasal delivery is non-invasive and provides a more targeted delivery than the systemic injectable approach, potentially offering a quicker response and reduced side effects. million by 2029, up from $122.287 million in 2021. Key to overcoming many of these challenges lies in the evolution of nasal spray device design.

Management 119

Management Manufacturing Marketing Side effects 119